Finch Therapeutics
@finchtherapeutics.com
Finch, an early pioneer in the emerging field of microbiome therapeutics, has established a leading portfolio of innovative microbiome assets with potential applicability to a wide range of product strategies and therapeutic areas.
Finch Therapeutics's Company Logos
Finch Therapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#F06623
Flamingo
240, 102, 35
20, 87, 54
0, 57, 85, 6
#F3CB29
Saffron
243, 203, 41
48, 89, 56
0, 16, 83, 5
#09539D
Venice Blue
9, 83, 157
210, 89, 33
94, 47, 0, 38
About Finch Therapeutics
Finch Therapeutics is an early pioneer in the field of microbiome therapeutics, offering a leading portfolio of innovative microbiome assets. With a focus on a wide range of product strategies and therapeutic areas, Finch has established itself as a key player in this emerging field. Their portfolio includes microbiome assets that have the potential to revolutionize medical treatments.
One notable asset in Finch's portfolio is CP101, which was being explored in a Phase 3 trial for recurrent C. However, the company recently decided to discontinue the trial and shift their focus to realizing the value of their intellectual property estate and other assets. With insights from human microbiota transplantation studies, Finch has developed a robust and cutting-edge portfolio of microbiome assets.
They are proud of their role as pioneers in this field, reflected in their strong intellectual property estate
Related Brands
Tags
Microbiome therapeutics
C. difficile infection therapeutics
Intestinal microbiome drug candidates
Intellectual property licensing
Microbiota transplantation–informed R&D
